| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Related Medications Threads on Diabetes Health Forums
Novocell is the Recipient of a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes
San Diego, CA (October 28, 2009) - Novocell, Inc., a preclinical stage diabetes company, today announced that it will receive a Disease Team award totaling $20 million from the California Institute for Regenerative Medicine (CIRM). The Disease Team includes a group of scientists at the University of California, San Francisco (UCSF), led by Dr. Jeff Bluestone, which is contracted to receive $2.8 million. The funding will advance Novocell's development of a first in kind cellular therapy for the treatment of diabetes.
0 comments - Oct 31, 2009 -
The enthusiasm for inhaled insulin has waned, to say the least, since Exubera was pulled off the market by Pfizer. Following the Exubera debacle, the development of two other inhaled insulins (AIR by Eli Lilly and Alkermes, and AERx by Novo Nordisk) was halted as well.
12 comments - Oct 5, 2009 -
Adults newly diagnosed with type 2 diabetes generally don't take to the idea of using insulin right off the bat. They're worried about gaining weight and fear low blood sugars. They're also concerned about whether they can manage the regimen and fear that taking insulin will lower their quality of life. Those concerns, however, might be assuaged by a study recently conducted by Ildiko Lingvay and his colleagues at the University of Texas Southwestern.
5 comments - Sep 12, 2009 -
A Japanese company whose biggest moneymaker is the sale of synthetic fabrics announced a few days ago that it has developed an insulin nasal spray for people with diabetes. The news brought an investor surge that lifted the value of its stocks by 10 percent.
0 comments - Aug 28, 2009 -
The American Diabetes Association estimates that about 18 million Americans have diabetes. Given that millions of people have lost their jobs during the current recession, the law of averages would suggest that at least a few hundred thousand folks with diabetes are now unemployed. Loss of a job, unfortunately, usually means a concurrent loss of health insurance. For those hundreds of thousands of people with diabetes, no health insurance means big trouble.
0 comments - Aug 18, 2009 -
If it's a pump, then where's the tubing? Well, it looks like another company has put a patch on that problem. Medingo Ltd., a company held by Elron Electronic Industries, has received FDA approval to market the Solo MicroPump Insulin Delivery System. The Solo System consists of an insulin-dispensing patch and a remote control device that increases or decreases the patch's rate of secretion.
5 comments - Aug 15, 2009 -
Until the twentieth century, type 1 diabetes was a fatal disease. Once we came to understand how insulin works in the body, however, everything changed. The discovery of the role of insulin was a group effort by people who didn't know each other, but built on each others' work. In 1869, a German medical student named Paul Langerhans figured out the regulatory role of insulin in the mammal body. In honor of his efforts, his name was given to the islets of Langerhans, where insulin is synthesized within the beta cells of the pancreas. Other Europeans and North Americans made important advancements right up until January 23, 1922, when a 14-year-old boy who was dying of diabetes at Toronto General Hospital was given the first successful injection of cow insulin.
2 comments - Aug 10, 2009 -
In April of 2008, our healthy nine-year-old son, Gaspar, was diagnosed with type 1 diabetes. After his two days in the ICU and a week in the hospital, a new life began for all of us. Although we couldn't immediately grasp all its implications and were simultaneously dealing with our shaken world, we gave the situation a "think outside the box" approach. When the endocrinologist told us, "That's the way it is. Just focus on the controls and all will be fine," we asked whether the condition might be cured or attenuated if we acted quickly at the beginning. We were met with the usual answer: "There's nothing you can do. Just focus on the controls."
6 comments - Aug 3, 2009 -
Banting Gives It Away - Insulin was discovered in 1921 by Fred Banting and Charles Best. In a generous gesture that unfortunately didn't start a trend, they sold the patent for a dollar so that cheap insulin would quickly become available. It worked like a charm: within two years, Eli Lilly had sold 60 million units of its purified extract of pig and cow pancreas.
17 comments - Jul 27, 2009 -
The International Diabetes Federation (IDF) has called for urgent assessment and responses from regulatory authorities into a possible link between the use of insulin glargine (an insulin analog) and increased risk of cancer. The proposed link is based on findings published on June 26, 2009, in Diabetelogia, the journal of the European Association for the Study of Diabetes (EASD).
2 comments - Jul 6, 2009 -